Amgen (NASDAQ: AMGN) director granted 665 RSUs in stock award

Rhea-AI Filing Summary

Klotman Mary E. reported acquisition or exercise transactions in this Form 4 filing.

Amgen director Mary E. Klotman received an equity award of 665 shares of common stock in the form of Restricted Stock Units. The RSUs were granted under Amgen’s 2009 Director Incentive Program and vested immediately, paying out in common shares on a one-to-one basis.

Following this grant, Klotman directly holds 2,211 shares of Amgen common stock, which include 18 dividend-equivalent units credited to her unvested RSUs under the company’s equity incentive plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Klotman Mary E.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	665	$0.00	--

Holdings After Transaction: Common Stock — 2,211 shares (Direct, null)

Footnotes (1)

1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. These shares include 18 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Key Figures

RSU grant size: 665 shares Holdings after grant: 2,211 shares Dividend equivalents: 18 DEs

3 metrics

RSU grant size 665 shares Common Stock RSUs granted to director on May 19, 2026

Holdings after grant 2,211 shares Total Amgen common shares directly owned after the transaction

Dividend equivalents 18 DEs Dividend equivalents credited to unvested RSUs, payable in shares

Key Terms

Restricted Stock Units (RSUs), Director Incentive Program, Equity Incentive Plan, Dividend equivalents (DEs), +1 more

5 terms

Restricted Stock Units (RSUs) financial

"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

Director Incentive Program financial

"granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended"

Equity Incentive Plan financial

"under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Dividend equivalents (DEs) financial

"These shares include 18 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"

deferral schedule financial

"Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klotman Mary E.

(Last) (First) (Middle)

ONE AMGEN CENER DRIVE

(Street)

THOUSAND OAKS CALIFORNIA 91320

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		A		665	A	$0	2,211(1)(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

2. These shares include 18 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Mary E. Klotman	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Amgen (AMGN) director Mary E. Klotman receive in this Form 4 filing?

Mary E. Klotman received an equity award of 665 Amgen common shares via Restricted Stock Units. These RSUs were granted under Amgen’s 2009 Director Incentive Program and vested immediately, paying out in shares of common stock on a one-to-one basis.

How many Amgen (AMGN) shares does Mary E. Klotman hold after this RSU grant?

After the grant, Mary E. Klotman directly holds 2,211 shares of Amgen common stock. This total includes shares delivered from vested RSUs and 18 dividend-equivalent units credited to her unvested RSUs under Amgen’s equity incentive plan.

What are the terms of the Restricted Stock Units granted to Amgen (AMGN) director Klotman?

The RSUs granted to Klotman vested immediately and are paid in Amgen common stock on a one-to-one basis. Vested RSUs may also be deferred at her election, with share delivery occurring later according to the chosen deferral schedule under the plan.

How are dividend equivalents (DEs) treated in Amgen (AMGN) director RSU awards?

Dividend equivalents are credited to the director’s unvested RSUs and track dividends on Amgen stock. For Klotman, 18 DEs are included and will be paid in common stock on a one-to-one basis as the related RSUs vest, plus cash for any fractional amount.

Was Mary E. Klotman’s Amgen (AMGN) Form 4 transaction an open-market stock purchase?

No, the transaction was a grant or award acquisition of 665 shares through Restricted Stock Units, not an open-market purchase. The RSUs were issued as director compensation under Amgen’s 2009 Director Incentive Program and vested immediately into common shares.